Description
JAK2 inhibitor pacritinib significantly benefits patient reported outcomes in myelofibrosis
Article: JAK2 inhibitor pacritinib significantly benefits patient reported outcomes in myelofibrosis
€3.03
€3.03
JAK2 inhibitor pacritinib significantly benefits patient reported outcomes in myelofibrosis
Top
Notifications
Reviews
There are no reviews yet.